Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-04-14
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines for severe diseases, led by approved therapy CASGEVY and a broader pipeline in cardiovascular, autoimmune, oncology and regenerative medicine.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved proof, but rerating still needs a second franchise
The approved hemoglobinopathy asset lowers existential risk and the balance sheet gives management time. The real 2031 upside comes from proving that at least one wholly owned program can become a meaningful commercial engine rather than leaving the company as a partner-mediated one-product story.

Analysis

Thesis
CRSP already has real CRISPR-medicine proof and a balance sheet that can fund multiple shots on goal; if CASGEVY keeps scaling and one wholly owned program becomes a credible second franchise, the stock can rerate from cash-backed optionality into a multi-asset gene-editing company.
Last Economy Alignment
AI should improve target selection and program throughput, but value capture still comes from IP, clinical evidence, manufacturing and regulatory trust rather than software surfaces. That makes CRSP moderately helped by the Last Economy, not fully transformed by it.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.4x (from 5 most recent analyses)
Reasoning
The upside case is a rerating from one approved product plus cash into a company with two value centers: a more established CASGEVY profit stream and at least one internally controlled franchise with real commercial credibility. The balance sheet buys time, the approved asset reduces existential risk, and AI-assisted discovery should improve portfolio throughput. The cap is that regulation, treatment-center capacity and partner control still limit how far investors will stretch the multiple.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risks are proof and control. CASGEVY has validated the modality, but realized economics still depend on a scarce treatment ecosystem and a Vertex-led commercial machine, while the bigger 2031 rerating requires at least one wholly owned program to clear clinical, manufacturing and regulatory gates. The balance sheet reduces financing risk more than it reduces scientific or commercialization timing risk.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.39
They own real gene-editing know-how, clinical evidence and a manufacturing site, so cheaper AI should help them produce and prioritize better drug candidates. But regulators, treatment-center capacity and Vertex control of the first launch still limit how much of that value they can capture.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$83.35
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case